Compare LRCX & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRCX | MRK |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7B | 268.7B |
| IPO Year | 1994 | 1994 |
| Metric | LRCX | MRK |
|---|---|---|
| Price | $211.64 | $119.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 15 |
| Target Price | ★ $241.79 | $123.67 |
| AVG Volume (30 Days) | ★ 8.6M | 6.8M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | 0.49% | ★ 2.86% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | 2.50 | ★ 7.28 |
| Revenue | $3,237,693,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $24.44 | $3.74 |
| Revenue Next Year | $23.81 | $5.47 |
| P/E Ratio | $84.65 | ★ $16.34 |
| Revenue Growth | ★ 51.74 | 1.31 |
| 52 Week Low | $57.97 | $75.40 |
| 52 Week High | $256.68 | $125.14 |
| Indicator | LRCX | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 57.94 |
| Support Level | $201.51 | $113.27 |
| Resistance Level | $254.28 | $125.14 |
| Average True Range (ATR) | 9.95 | 2.18 |
| MACD | -0.69 | 0.25 |
| Stochastic Oscillator | 7.70 | 81.80 |
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).